ES3056005T3 - Arimoclomol for treating gaucher disease - Google Patents

Arimoclomol for treating gaucher disease

Info

Publication number
ES3056005T3
ES3056005T3 ES21733160T ES21733160T ES3056005T3 ES 3056005 T3 ES3056005 T3 ES 3056005T3 ES 21733160 T ES21733160 T ES 21733160T ES 21733160 T ES21733160 T ES 21733160T ES 3056005 T3 ES3056005 T3 ES 3056005T3
Authority
ES
Spain
Prior art keywords
day
piperidinyl
propoxy
pyridine
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES21733160T
Other languages
English (en)
Spanish (es)
Inventor
Thomas Jensen
Anders Hinsby
Cathrine Fog-Tønnesen
Linda Ingemann
Dali Christine I
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zevra Denmark AS
Original Assignee
Zevra Denmark AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zevra Denmark AS filed Critical Zevra Denmark AS
Application granted granted Critical
Publication of ES3056005T3 publication Critical patent/ES3056005T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ES21733160T 2020-06-24 2021-06-24 Arimoclomol for treating gaucher disease Active ES3056005T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20182067 2020-06-24
PCT/EP2021/067366 WO2021260120A1 (en) 2020-06-24 2021-06-24 Arimoclomol for treating gaucher disease

Publications (1)

Publication Number Publication Date
ES3056005T3 true ES3056005T3 (en) 2026-02-17

Family

ID=71143584

Family Applications (1)

Application Number Title Priority Date Filing Date
ES21733160T Active ES3056005T3 (en) 2020-06-24 2021-06-24 Arimoclomol for treating gaucher disease

Country Status (14)

Country Link
US (1) US20230226036A1 (enExample)
EP (1) EP4171559B1 (enExample)
JP (2) JP2023531750A (enExample)
KR (1) KR20230035586A (enExample)
CN (1) CN116075305A (enExample)
AU (1) AU2021295437A1 (enExample)
BR (1) BR112022026396A2 (enExample)
CA (1) CA3183559A1 (enExample)
DK (1) DK4171559T3 (enExample)
ES (1) ES3056005T3 (enExample)
IL (1) IL299250A (enExample)
MX (1) MX2023000033A (enExample)
PT (1) PT4171559T (enExample)
WO (1) WO2021260120A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2013125923A (ru) * 2010-11-30 2015-01-10 Орфазиме Апс СПОСОБЫ УВЕЛИЧЕНИЯ ВНУТРИКЛЕТОЧНОЙ АКТИВНОСТИ Hsp70

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU222994B1 (hu) 1995-11-02 2004-01-28 BIOREX Kutató és Fejlesztő Rt. Hidroxilaminszármazékok és azok alkalmazása sejtek molekuláris chaperon-termelésének fokozására alkalmas gyógyszerkészítmények előállítására
HUP9900475D0 (en) 1999-02-26 1999-04-28 Biorex Kutato Fejlesztoe Kft O-(3-piperidino-2-hydroxy-1-propyl)-hiyroximic acid-halogenid derivative, it's use for treating insulin resistance, and pharmaceutical compositions containing them as active component
HUP0001583A2 (hu) 2000-04-18 2002-11-28 BIOREX Kutató és Fejlesztő Rt. Egy piridin-1-oxid-származék és eljárás annak átalakítására gyógyászati hatású vegyületekké
EP2484371B1 (en) * 2008-06-26 2014-12-17 Orphazyme APS Use of Hsp70 as a regulator of enzymatic activity
NZ623910A (en) * 2009-07-28 2016-06-24 Shire Human Genetic Therapies Compositions and methods for treating gaucher disease
US10709700B2 (en) * 2014-09-15 2020-07-14 Orphazyme A/S Arimoclomol formulation
SI3448382T1 (sl) * 2016-04-29 2021-03-31 Orphazyme A/S, c/o COBIS A/S Arimoclomol za zdravljenje motenj, povezanih z glukocerebrozidazo
KR102279347B1 (ko) * 2016-12-15 2021-07-21 한국생명공학연구원 피리딘계 화합물을 유효성분으로 함유하는 dyrk 관련 질환의 예방 또는 치료용 약학적 조성물

Also Published As

Publication number Publication date
EP4171559A1 (en) 2023-05-03
US20230226036A1 (en) 2023-07-20
MX2023000033A (es) 2023-04-10
WO2021260120A1 (en) 2021-12-30
JP2023531750A (ja) 2023-07-25
DK4171559T3 (da) 2025-12-15
CN116075305A (zh) 2023-05-05
KR20230035586A (ko) 2023-03-14
EP4171559B1 (en) 2025-09-10
JP2026042936A (ja) 2026-03-11
CA3183559A1 (en) 2021-12-30
PT4171559T (pt) 2025-12-16
IL299250A (en) 2023-02-01
BR112022026396A2 (pt) 2023-03-14
JP7849574B2 (ja) 2026-04-21
AU2021295437A1 (en) 2023-02-02

Similar Documents

Publication Publication Date Title
ES2979034T3 (es) Procedimientos de tratamiento del síndrome de Lennox-Gastaut mediante el uso de fenfluramina
ES2689520T3 (es) Formulación terapéutica para reducir los efectos secundarios de fármacos
US20040167226A1 (en) Methods for the treatment of pain and traumatic injury using benzamides and compositions containing the same
JP2021502403A (ja) 遺伝性てんかん性障害の処置に使用するガナキソロン
US20230277507A1 (en) Tinostamustine for use in treating sarcoma
US9452132B2 (en) Methods for administration and formulations for the treatment of regional adipose tissue
ES2822562T3 (es) Composiciones intranasales para el tratamiento de enfermedades y trastornos neurológicos y degenerativos
JP7849574B2 (ja) ゴーシェ病を処置するためのアリモクロモル
BR112020016500A2 (pt) Agente preventivo ou terapêutico e composição farmacêutica para doença inflamatória ou doença óssea
CN105764510A (zh) H3受体拮抗剂与胆碱酶抑制剂组合用于阿尔茨海默氏病治疗中的用途
ES3001104T3 (es) Acido (1R,3S)-3-((5-ciano-4-feniltiazol-2-il)carbamoil)ciclopentano-1-carboxílico y derivados del mismo para su uso en el tratamiento de enfermedades de las vías respiratorias
JP4746714B2 (ja) 線維筋痛症治療用医薬組成物
HK40090895A (en) Arimoclomol for treating gaucher disease
HK40090895B (en) Arimoclomol for treating gaucher disease
JP6429401B2 (ja) 変異を有するｉ型コラーゲンの小胞体内過剰蓄積正常化剤
US20190247405A1 (en) Treatment of sma
ES2991518T3 (es) Composición para la mejora de la sensibilidad a la radiación que contiene aripiprazol como ingrediente activo
Ghimire et al. Comparative efficacy of steroid nasal spray versus antihistamine nasal spray in allergic rhinitis
Khaleel et al. Ciprofloxacin Chemistry, Medical Evaluation and Adverse Effect with Special Attention to Ciprofloxacin Chondrotoxicity
TW202608444A (zh) 維奈托克（ｖｅｎｅｔｏｃｌａｘ）口服藥物及其用途
WO2025220030A1 (en) Pharmaceutical combinations
ES2982396A1 (es) 2-hidroxi-octadecen-9-cis-oato para uso en el tratamiento de patologias oncologicas y del dolor neuropatico
TW202604498A (zh) 劑量方案
WO2022032146A1 (en) Methods for inhibiting growth of era positive cancers
CN121401261A (zh) 喹诺林化合物治疗甲状腺癌的用途